 SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Bio Nasdaq: NGM will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET 5:00 a.m. PT to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. 